Bright v Femcare Limited

Link copied
Case Copied 44 min read

FEDERAL COURT OF AUSTRALIA

Bright v Femcare Limited [2001] FCA 1477

PROCEDURE – representative proceedings under Pt IVA of the Federal Court of Australia Act 1976 (Cth) (“the Act”)– whether proceedings satisfy the criteria in s 33C of the Act - whether there are substantial common issues of fact or law – whether the Court ought to make an order pursuant to s 33N of the Act that the proceeding no longer continue under Pt IVA of the Act

Federal Court of Australia Act 1976 (Cth), s 33C, s 33N

Silkfield Pty Ltd v Wong (1998) 90 FCR 152 at 157 – 158 referred to
Murphy v Overton Investments Pty Ltd [1999] FCA 1123 at [67], [80] referred to
Vasram v AMP Life Limited [2000] FCA 1676 at [14] referred to
Murphy v Overton Investments Pty Ltd [1999] FCA 689 at [15] referred to
Qantas Airways v Cameron (1996) 66 FCR 246 at 251 ­ 252, 293 referred to
Wong v Silkfield Pty Ltd (1999) 199 CLR 255 followed
Campomar Sociedad, Limitada v Nike International Ltd (2000) 169 ALR 677 at 704 [103] referred to
Fraser v NRMA Holdings Ltd (1995) 55 FCR 452 at 467 referred to
Ryan v Great Lakes Council (1998) 155 ALR 447 at 456 referred to
ACCC v Giraffe World Australia Pty Ltd (1998) 84 FCR 512 at 534 referred to

KERRIE BRIGHT v FEMCARE LIMITED & ANOR
N 410 of 1999

STONE J
19 OCTOBER 2001
SYDNEY


IN THE FEDERAL COURT OF AUSTRALIA

NEW SOUTH WALES DISTRICT REGISTRY

N 410 OF 1999

BETWEEN:

KERRIE BRIGHT
APPLICANT

AND:

FEMCARE LIMITED
FIRST RESPONDENT

ENDOVASIVE PTY LIMITED
(ACN 061 512 132)
SECOND RESPONDENT

JUDGE:

STONE J

DATE OF ORDER:

19 OCTOBER 2001

WHERE MADE:

SYDNEY

THE COURT ORDERS:

pursuant to s 33N of the Federal Court of Australia Act 1976 (Cth), that this proceeding no longer continue under Pt IVA of the Act.

THE COURT DIRECTS THAT:

1.the proceedings be stood over to a date to be advised; and

2.the parties file and serve any written submissions on the issue of costs by 2 November 2001.

Note:    Settlement and entry of orders is dealt with in Order 36 of the Federal Court Rules.


IN THE FEDERAL COURT OF AUSTRALIA

NEW SOUTH WALES DISTRICT REGISTRY

N 410 OF 1999

BETWEEN:

KERRIE BRIGHT
APPLICANT

AND:

FEMCARE LIMITED
FIRST RESPONDENT

ENDOVASIVE PTY LIMITED
(ACN 061 512 132)
SECOND RESPONDENT

JUDGE:

STONE J

DATE:

19 OCTOBER 2001

PLACE:

SYDNEY

REASONS FOR JUDGMENT

INTRODUCTION

  1. On 10 May 1999, the applicant commenced representative proceedings under Pt IVA of the Federal Court of Australia Act 1976 (Cth) (“the Act”). The proceedings have already given rise to six judgments of this Court: (1999) 166 ALR 743 (constitutional validity of Pt IVA of the Act; affirmed on appeal, (2000) 100 FCR 331), (2000) 175 ALR 50 (third amended statement of claim struck out), [2000] FCA 1179 (issues relating to a subpoena addressed to the Therapeutic Goods Administration), [2000] FCA 1344 (issues relating to subpoenas addressed…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Bright v Femcare Limited and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2001] FCA 1477
Decision Date

CaseChat Overview and Summary

Bright v Femcare Limited involved a group of women who sought to bring a class action against Femcare Limited and Endovasive, alleging that they had been injured as a result of the use of the Filshie Clip in female sterilisation procedures. The women claimed that the respondents failed to provide adequate warnings about the risks associated with the Filshie Clip, including the need for regular calibration checks and the importance of using calibrated equipment. The Federal Court of Australia was tasked with determining whether the representative proceeding under Pt IVA of the Federal Court of Australia Act could proceed.

The primary legal issues before the court were whether the claims could be effectively dealt with in a representative proceeding and whether the common issues would materially advance the determination of the individual claims. The court had to assess whether the proceeding would be efficient and in the interests of justice, considering the potential costs and whether the common issues were likely to be revisited in the context of each individual claim. Additionally, the court considered whether the mandatory requirements of the legislation had been met.

In reaching its conclusion, the court found that the representative proceeding was not an efficient or effective means of dealing with the claims due to the significant individual issues that would need to be revisited in each case. The common issues identified in the proceeding were either too general to materially advance the individual claims or would require re-evaluation in each individual context. The intertwining of common and individual issues would likely result in excessive costs if the proceeding continued under Pt IVA. Consequently, the court decided that the proceeding should not continue under Pt IVA, and it proposed to order that the proceeding be stood over for further directions. The court also noted that it would allow parties to make written submissions on costs, with an opportunity for any party to be heard if desired.

The court's decision was grounded in the recognition that while there were common issues among the group members' claims, these issues were not sufficiently developed to advance the resolution of individual claims. The potential for revisiting these issues in the context of each individual claim suggested that a representative proceeding would not be efficient. Therefore, the court concluded that it was in the interests of justice to discontinue the proceeding under Pt IVA and to manage the claims individually, potentially in another jurisdiction, to minimize costs and ensure effective resolution.

Orders

Orders of the court

Full text does not contain this section.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

STONE J
Mr Walker SC submitted that one cannot determine whether there was a duty to warn in any individual case because the existence and content of the duty to warn depends upon the putative recipient of the warning. Whether or not that is strictly accurate, it is clear that no claim against the respondents based on their failure to warn could succeed without assessing the relevant knowledge of the medical practitioner who carried out the procedure at that time. As Mr Walker SC reminded the Court, the group members’ claims are ultimately directed to establishing responsibility for their alleged losses and compensation for those losses. They are not directed towards settling in the abstract propositions about failures to warn and the making of representations. In assessing the medical practitioner’s knowledge, it would be necessary to consider, not only information provided to the individual doctor, but also information provided by the respondents more generally. It may be that this involves both issues of causation as well as of duty but, in any event, the result is that the respondents’ promotional material would need to be considered in the context of in each individual case, even if it had already been considered in a representative proceeding. CONCLUSION AND ORDERS Having reviewed the evidence and the submissions made by both parties, I have concluded that the representative proceeding will not provide an efficient and effective means of dealing with the claims of the group members and that, in the interests of justice, it should not continue under Pt IVA of the Act. Although there are issues of substance common to the claims of group members, in the main, they are either issues that are stated at such a level of generality that their resolution will not materially advance the determination of the claims of individual group members and/or they would need to be revisited in the context of each group member’s claim. In addition, the intertwining of the common and individual issues is such that I also believe that the costs of continuing the proceeding under Pt IVA are likely to exceed the costs that would be incurred by dealing with the claims of group members individually. There are established techniques of case management by which these costs can be minimised, for example by ensuring that all individual claims are dealt with by the same judge. It may be that, as the respondents suggested, those claims could dealt with more cost effectively in another jurisdiction. My conclusion that the proceeding should not continue under Pt IVA makes it unnecessary to consider Endovasive’s contention that the mandatory requirements of s 33H have not been met. I propose to order that this proceeding no longer continue under Pt IVA of the Act. I will stand the proceeding over for further directions on a date to be advised by my associate. Both respondents have claimed costs but, as there has been no argument on this issue, I do not propose to make any order as to costs at this time. I will allow all parties to make written submissions as to costs, such submissions to be filed no later than 2 November 2001. If any party wishes to be heard on the matter of costs, that party should contact my associate to arrange a suitable date.

Ratio Decidendi

Legal Principle Established

Established by: STONE J

The statement of claim identifies three warnings that, it is alleged, both Femcare and Endovasive (after 1993) had a duty to give. They are:(a) the “calibration risk” warning;(b) the “regular check” warning; and (c) the “no servicing” warning.Calibration risk warning The calibration risk warning, is described as a clear and prominent warning to the effect that:·it is critical to the performance of an applicator that it be in calibration; ·an applicator might become out of calibration as a result of ordinary use or as a result of mishandling or vigorous handling; ·it cannot be predicted with precision how much use will cause an applicator to become out of calibration; ·the use of an out of calibration applicator increases the risk of ineffective sterilisation and therefore a Filshie applicator should be checked immediately before use; and·it is therefore important that hospitals and doctors have had a reliable means of checking whether an applicator is in calibration before using it. Femcare, it is alleged, did not give such a warning to its Australian distributors or instruct them to give such a warning to hospitals, doctors and subdistributors. Endovasive and other distributors did not give such a warning to hospitals or doctors. Doctors and hospitals had a reasonable or legitimate expectation that Femcare and Endovasive would give such a warning, or alternatively, it was misleading or deceptive for them not to do so, or alternatively, Femcare and Endovasive owed a duty to hospitals and doctors to give the warning.Regular check warning Similar allegations are made in relation to the regular check warning. This is a warning that, because of the propensity of an applicator to fall out of calibration and the impossibility of predicting the precise circumstances in which this might occur, it is essential that an applicator be regularly checked by Femcare or its authorised agent, that accurate records of use be kept and that applicators which have not been regularly checked, or of which records of use have not been kept, not be used in procedures. No servicing warning The no servicing warning is described as a clear and prominent warning incorporating the regular check warning and stating that Femcare or its agent has an available means of checking the calibration of an applicator and that hospitals and doctors are not providing applicators to Femcare or its agent for checking. The pleading makes allegations in relation to this warning which are substantially the same as those made in relation to the other two warnings. There is, however, one difference the materiality of which is not immediately obvious. The duty to give the no servicing warning, unlike the duty to give the other warnings, is pleaded as a duty owed to the applicant and group members as well as a duty owed to hospitals, doctors and (in the case of Femcare) Australian distributors and (in the case of Endovasive) Australian subdistributors.Misrepresentation In addition to the allegations of misrepresentation stemming from the failure to give warnings, the applicant also alleges positive misrepresentation. It is said that Femcare (since 1982) and Endovasive (since November 1993) have made what is described as the “safety representation”. This is a representation that the Filshie procedure was and would be a safe and effective method of female sterilisation. That representation is said to have been made both in the product literature accompanying the equipment and, by implication, from the fact of the sale and promotion of the Filshie equipment. The safety representation is alleged to have been made to doctors, hospitals, distributors and subdistributors and is alleged to have been inaccurate because it was not qualified by either the calibration risk warning or the regular service warning. Misleading and deceptive conduct